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 1.  Introduction 
 Rapid developments in biological nanotechnology have 
led to the identifi cation of numerous types of photolumi-
nescent nanomaterials [ 1 ] with promising applications in 
imaging, [ 1c–e ,  2 ] catalysis, [ 1c ] and therapeutics. [ 1a ] These include 
gold (Au) nanoparticles (NPs), [ 1d ] quantum dots, [ 3 ] titanium 
dioxides, [ 1c ,  1e ] and upconversion nanocrystals [ 4 ] (UCNs). The 
tailored applications of these nanomaterials are achieved typ-
ically through their surface modifi cation or modular integra-
tion with other functionally designed NPs that bring together 
complementary capabilities needed for specifi c cell targeting 
and delivery of payloads. [ 5 ] In particular, modular integration 
of NPs with near-infrared (NIR)-excited UCNs has shown 
promising potential for deep-tissue imaging and controlled DOI: 10.1002/smll.201501575
 Upconversion nanocrystals (UCNs) display near-infrared (NIR)-responsive 
photoluminescent properties for NIR imaging and drug delivery. The development of 
effective strategies for UCN integration with other complementary nanostructures for 
targeting and drug conjugation is highly desirable. This study reports on a core/shell-
based theranostic system designed by UCN integration with a folate (FA)-conjugated 
dendrimer for tumor targeting and with photocaged doxorubicin as a cytotoxic 
agent. Two types of UCNs (NaYF 4 :Yb/Er (or Yb/Tm); diameter = ≈50 to 54 nm) are 
described, each displaying distinct emission properties upon NIR (980 nm) excitation. 
The UCNs are surface modifi ed through covalent attachment of photocaged 
doxorubicin (ONB-Dox) and a multivalent FA-conjugated polyamidoamine 
(PAMAM) dendrimer G5(FA) 6 to prepare UCN@(ONB-Dox)(G5FA). Surface 
plasmon resonance experiments performed with G5(FA) 6 dendrimer alone show 
nanomolar binding avidity ( K D = 5.9 × 10 
−9 M ) to the folate binding protein. This 
dendrimer binding corresponds with selective binding and uptake of UCN@
(ONB-Dox)(G5FA) by FAR-positive KB carcinoma cells  in vitro . Furthermore, 
UCN@(ONB-Dox)(G5FA) treatment of FAR(+) KB cells inhibits cell growth in 
a light dependent manner. These results validate the utility of modularly integrated 
UCN-dendrimer nanocomposites for cell type specifi c NIR imaging and light-
controlled drug release, thus serving as a new theranostic system. 
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payload delivery. [ 2 ,  5b ,  6 ] However, despite the proven benefi ts 
imparted by such modularly integrated UCNs, the design 
principles of each integrated UCN nanostructure have not 
been addressed through a systematic assessment of the requi-
site design parameters. In this study, we report on the design 
and characterization of a novel core/shell nanostructure 
consisting of three functionally orthogonal modules: UCN [ 7 ] 
covalently coated with poly(amidoamine) (PAMAM) den-
drimer [ 8 ] and photocaged doxorubicin [ 9 ] (ONB-Dox). This 
study addresses the key design aspects important for the 
effi cacy of these nanocomposites in tumor receptor-targeted, 
temporally controlled drug delivery by assessing the effec-
tiveness of each of the modular components in their func-
tional roles, including cell specifi c targeting, imaging, and 
drug payload release. 
 As a core module, UCNs are an emerging class of photo-
luminescent nanostructures made of host materials such as 
NaYF 4 doped with lanthanide ions (Yb, Er, Tm, and Nd). 
[ 7,10 ] 
These UCNs are excited by NIR light (980, 800 nm [ 10e ] 
and have the unique photophysical ability to convert the 
absorbed NIR to shorter visible (vis) and ultraviolet (UV) 
light with excellent photostability and brightness. [ 5b ,  7b ,  10d,e ] 
Thus, the incorporation of UCNs offers two primary advan-
tages to modular applications. First, the NIR-excited UCN 
core allows for sustained tracking of tumor cells due to the 
lack of photobleaching which commonly limits the utility of 
organic fl uorophores. Furthermore, NIR radiation can pene-
trate signifi cantly deeper into tissue than UV radiation or vis-
ible light which is used for photodynamic therapy (PDT). [ 6b,c ] 
Together, these properties make UCNs highly valuable for 
use in  in vivo imaging studies. [ 2 ,  5b ,  6e ,  11 ] Second, UV emis-
sion from the UCN core upon excitation by NIR light can 
be harnessed to trigger the release or activation of a conju-
gated payload through a photochemical mechanism. [ 5g ,  6a–d ,  12 ] 
The effectiveness of such modular applications of UCNs has 
been demonstrated in the generation of reactive oxygen spe-
cies (ROS) for photodynamic therapy (PDT), [ 6b,c ] as well 
as for the release of entrapped or attached guest molecules 
(cisplatin, [ 5d ] Dox, [ 12b ,  13 ] bovine serum albumin [ 5g ] ) and acti-
vation of photocaged molecules (platinum agent, [ 14 ] siRNA 
payload, [ 6d ,  15 ] FA ligand [ 6a ] ). 
 As a shell module, a fi fth generation (G5) PAMAM den-
drimer is coated onto the UCN surface and is responsible for 
the specifi c targeting of the composite to a tumor cell. The 
G5 dendrimer is the prototype of dendritic polymers. It is 
characterized by a globular shape (diameter = 5.4 nm) [ 8,16 ] 
consisting of a large number of amine-terminated branches 
( n theor = 124), each chemically amenable to ligand or drug 
conjugation in a predefi ned orientation with conformational 
fl exibility. Surface modifi cation of the dendrimer with mul-
tiple targeting ligands offers the added advantage of multi-
valent binding, [ 17 ] allowing for extremely tight and selective 
adsorption to target receptors on the cell surface. Together, 
these properties make the G5 dendrimer an ideal platform 
for cell targeting. [ 18 ] The use of G5 dendrimers for targeting 
cancer biomarkers including folate receptor-α (FAR α ), 
[ 18a,b,d ] 
ribofl avin (RF) receptor, [ 5f ,  19 ] α v β 3 integrin, [ 20 ] and prostate-
specifi c membrane antigen (PSMA [ 21 ] has been studied 
extensively. Thus, the G5 dendrimer has been established as 
one of the most effective NPs [ 18b ,  18d ,  21b ,  22 ] for tumor-targeted 
delivery of genes [ 19c ,  20b ,  23 ] and therapeutic payloads. [ 18a,d ,  21a ,  24 ] 
 The present study incorporates these two nanoparticle 
modules in combination with photocaged doxorubicin as 
an anticancer therapeutic agent to generate a novel core/
shell nanostructure, UCN@(ONB-Dox)(G5FA), which 
refers to a UCN core coated with a FA-conjugated G5 den-
drimer G5(FA) and linked to a photocaged Dox [ 9 ] molecule 
( Figure  1 ). We designed two types of NIR-excited UCNs, 
one with the ability to emit vis light (540, 650 nm) suitable 
for imaging, and the other with the ability to emit UV light 
(340–360 nm) for controlled drug release. The modular 
nanostructure also carries a drug payload through covalent 
attachment to the UCN core, rather than to the dendrimer 
shell—the latter of which has been used in our earlier 
small 2015, 11, No. 45, 6078–6090
 Figure 1.  Modular assembly of a near-infrared (NIR)-excited upconversion nanocrystal (UCN) covalently linked with multivalent folate (FA)-
conjugated dendrimer for folate receptor (FAR)-targeted cell imaging and with photocaged doxorubicin for light triggered release of doxorubicin.
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methods for dendrimer-based drug delivery. [ 9 ,  18a ,  25 ] The 
rationale for this site of drug conjugation relates to receptor 
binding avidity and drug release kinetics which are described 
below. However, FA was attached to the dendrimer shell 
because of its well validated platform capacity for tight and 
selective FAR binding via multivalency, [ 18c ] and also because 
of the greater surface accessibility of FAR to the FA on the 
dendrimer as compared to presentation on the inner UCN 
surface. This study evaluates the design principles involved 
in generating and optimizing a series of UCN@(G5FA) and 
UCN@(ONB-Dox)(G5FA) nanostructures, and demon-
strates their effectiveness with regards to FAR-specifi c cell 
binding, NIR-based optical detection, and light controlled 
cytotoxicity. The fi ndings of these studies provide important 
insights into the modular design of UCN-based core/shell 
nanostructures and their relationship with the biological 
activity of the nanoparticle, allowing for rational optimiza-
tion of design components. 
 2.  Results and Discussion 
 2.1.  Synthesis of UCNs 
 A number of methods have been developed for UCN syn-
thesis, each with variations in the reaction condition or 
approach. [ 4a ,  6e–h ,  26 ] We applied a hot injection method [ 7b ] 
for synthesizing two types of UCN x ( x = 1, 2) which display 
distinct upconversion properties ( Figure  2 ). While each of 
these is excited by NIR light absorption (λ abs = 980 nm), 
the fi rst type of UCN, UCN 1 , was designed to emit light in 
the vis range, while the second type of UCN, UCN 2 , was 
designed to emit light at shorter UV–vis wavelengths. First, 
we synthesized UCN type 1 (UCN 1 = NaYF 4 : 20% Yb/2% 
Er) by the cothermolysis (290–330 °C) of CF 3 COONa and 
(CF 3 COO) 3 Re, (Re = Y, Yb, Er; Y:Yb:Er = 1.0:0.26:0.026) 
with oleic acid and sodium oleate as mixed ligands as 
described elsewhere. [ 7b ] This method also allowed us to vary 
the diameter of UCN 1 by adjusting the amount of sodium 
oleate added in the thermolysis process. Second, we prepared 
UCN type 2 (UCN 2 = NaYF 4 : 25% Yb/0.3% Tm) in a similar 
manner, except a different (CF 3 COO) 3 Re (Re = Y, Yb, Tm) 
mixture and ratio (Y:Yb:Tm = 1.0:0.33:0.04) was used. After 
preparation of the UCNs, selected UCN 1 and UCN 2 , each 
with d = 54 or 50 nm, respectively, were surface modifi ed by 
coating with a thin amine-terminated silica layer (NH 2 )SiO 2 . 
This modifi cation was performed following a nonionic water-
in-oil microemulsion method [ 27 ] by treatment with (3-amino-
propyl)triethoxysilane (APTES) via a silanization reaction. 
 The size and distribution of UCNs were determined by 
performing transmission electron microscopy (TEM). TEM 
images acquired for a representative NaYF 4 :Yb/Er sample 
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 Figure 2.  a) Synthetic scheme for upconversion nanocrystals UCN x (type  x = 1 or 2) and (NH 2 )SiO 2 -coated UCN x : i) RE(CF 3 CO 2 ) 3 (RE = Y, Yb and 
Er (for UCN 1 ) or Tm (for UCN 2 )), CF 3 CO 2 Na, oleic acid sodium salt, 1-octadecene, 330 °C, 20 min; ii) (3-aminopropyl)triethoxysilane, ammonia, 
polyoxyethylene nonylphenylether ( M n = 441); b,c) Transmission electron microscope (TEM) images of representative UCN 1 (NaYF 4 :20% Yb/2% 
Er) and UCN 2 (NaYF 4 :25%Yb/0.3% Tm). Right: Selected area electron diffraction (SAED) patterns; d) Upconversion luminescence spectra of 
UCN 1 acquired by excitation at 980 nm are compared as a function of UCN diameter: black (diameter =  d = 54 nm), red ( d = 30 nm), and blue 
( d = 20 nm), each synthesized individually; e) An upconversion luminescence spectrum of UCN 2 ( d = 50 nm) by excitation at 980 nm. Inset: a photograph 
showing emission of green light (c) or faint blue light (e) by exposure of UCN x dispersed in chloroform (2 mg mL 
−1 ) to NIR laser light (980 nm).
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showed that UCN 1 is comprised of nanocrystals with an 
average diameter of ≈54 nm and a narrow size distribution 
(range = 45–60; Figure  2 b). Some of these nanocrystals were 
hexagonal in shape, but others appeared less defi ned. How-
ever, selected area electron diffraction (SAED) patterns of 
NaYF 4 :Yb/Er (right) showed diffraction rings corresponding 
to the (100), (110), (200), and (201) planes, indicating a hex-
agonal lattice. TEM analysis performed for NaYF 4 :Yb/Tm 
(UCN 2 ) also showed hexagonal-shaped nanocrystals with an 
average diameter of ≈50 nm with a very narrow distribution 
(Figure  2 c). 
 We measured the upconversion emission proper-
ties of NaYF 4 :Yb/Er nanocrystals (UCN 1 ;  d = 54 nm) by 
NIR excitation at 980 nm (Figure  2 d). These nanocrystals 
showed two major emission peaks including a green band 
(max = 542 nm;  4 S 3/2 →  
4 I 15/2 transition for Er 
3+ ) and a red 
band (max = 651 nm;  4 F 9/2 →  
4 I 15/2 transition for Er 
3+ ). Fluo-
rescence intensity at the green band was greater than at the 
red band. Such emission peaks and relative intensities for 
UCN 1 are consistent with the values determined for other 
Er, Yb-doped NaYF 4 nanocrystals in previous studies. 
[ 28 ] 
In addition, it is notable that the size of the UCN 1 has a 
signifi cant impact on the effi ciency of its upconversion 
luminescence. [ 6f ,  29 ] A decrease in the diameter from ≈50 to 
30 or 20 nm led to a 10–15-fold reduction in emission inten-
sity. Such size variation, however, did not change the frac-
tional intensity ( f g/r ) between the green and red bands, which 
remained largely similar. Thus the UCN 1 with a diameter of 
54 nm was used for the subsequent integration steps. The 
upconversion luminescence properties of NaYF 4 :Yb/Tm 
nanocrystals UCN 2 ( d = 50 nm) were measured by excitation 
at 980 nm, which gave three emission peaks containing a UV 
band (340–360 nm), a blue band (450–475 nm) [ 30 ] and a broad 
peak at 800 nm (Figure  2 e). Thus, UCN 2 emits a combina-
tion of vis and UV light that serves as the mechanism for UV 
light-controlled drug release. 
 2.2.  Synthesis of FA-Linker 
 Multivalent conjugation of FA to G5 dendrimers serves as 
an effective strategy for tight binding of the conjugate to 
the FARs overexpressed (+) on certain tumor cells. [ 18a,b,d ] 
Our method for FA conjugation involves prederivatization 
of FA with a linker terminated with a primary amine as a 
chemical handle for amide coupling to a carboxylic acid-ter-
minated dendrimer molecule. We chose 2,2′-(ethylenedioxy)-
bis(ethylamine) as a linker as it has a medium length that 
allows for conformational fl exibility. The FA derivatization 
consisted of two steps in sequence: preactivation of FA by 
treatment with PyBOP ((benzotriazol-1-yloxy)tripyrrolidi-
nophosphonium hexafl uorophosphate) and 1-hydroxybenzo-
triazole (1-HOBt), and subsequent reaction with the diamine 
in situ ( Scheme  1 ). After the linker derivatization, the pri-
mary amine left at the opposite end of the linker was tem-
porarily protected as an  N -Boc group for the convenience of 
purifi cation by fl ash column chromatography which enabled 
the separation of two regioisomeric adducts of the linker at 
 l -Glu, γ-adduct  1 (19.3%), and α-adduct (6.6%), at a ≈2.9:1 
ratio. The major γ-isomer  1 was fully analyzed for its identity 
by standard analytical characterization methods, including  1 H 
NMR and mass spectrometry (Figure S1, Supporting Infor-
mation), and the linker  N -Boc group was deprotected by 
TFA treatment, yielding FA-linker  2 . 
 2.3.  Synthesis of Photocaged Doxorubicin (ONB-Dox) 
 The drug module in the nanocomposite consists of a 
photocaged doxorubicin molecule. Photocaging refers to the 
temporary inactivation of a drug or ligand molecule with a 
molecular cage which is cleavable by light exposure. [ 31 ] This 
technology serves as an effective means to release or acti-
vate drug/imaging molecules through an actively controlled 
mechanism [ 22c ,  32 ] as opposed to passive release mecha-
nisms [ 33 ] which are controlled by tumor-associated factors 
such as lower pH or overexpressed proteolytic enzymes. We 
have demonstrated the effectiveness of this drug release 
mechanism using a dendrimer platform in which photocaged 
doxorubicin (Dox) [ 9 ] or methotrexate [ 34 ] carried by an FAR-
targeted G5 dendrimer is activated and released from the 
dendrimer in a controlled manner using UV light as the 
trigger. Photocaged Dox  3 was prepared by derivatization of 
Dox with an  ortho -nitrobenzyl (ONB) group at its daunosa-
mine moiety and fully characterized as described elsewhere [ 9 ] 
(Scheme  1 , Scheme S2, Supporting Information). Removal of 
the linker  N -Boc group resulted in ONB-Dox  4 which con-
tains a free amine moiety at the linker to be used for covalent 
attachment to the dendrimer or UCN. 
 2.4.  Synthesis of G5(FA)(ONB-Dox) Conjugate 
 Glutaric acid (GA)-modifi ed dendrimer  6 G5(GA) [ 9 ] was 
employed for conjugation with FA-linker  2 alone or in 
combination with photocaged Dox  4 following a  N -(3-
dimethylaminopropyl)- N ′-ethylcarbodiimide (EDC)-based 
amide coupling method as described elsewhere [ 9 ] (Scheme  1 ). 
First, conjugate  7 G5(FA) n ( n mean = 6) was prepared by cova-
lent attachment of  2 and purifi ed by dialysis to remove unre-
acted ligand and reagents present in the reaction mixture 
using membrane tubing (MWCO 10 kDa). Its purity (polymer 
homogeneity ≥94%) and structural identity were fully veri-
fi ed by  1 H NMR, UV–vis spectroscopy (λ max = 354 nm, 
ε = 62 800  m −1 cm −1 ; FA), matrix-assisted laser desorption 
ionization time-of-fl ight (MALDI-TOF) mass spectrometry 
( M r = 38 600 g mol 
−1 ) and gel permeation chromatography 
(GPC;  M p = 42 000 g mol 
−1 ) (Table S1, Figures S2–S4, Sup-
porting Information). Second, conjugate  8 G5(FA) n (ONB-
Dox) m was prepared similarly by coattachment of  2 
and  4 to dendrimer G5(GA). The resulting conjugate  8 
G5(FA) n (ONB-Dox) m ( n mean = 6;  m mean = 6.9) was purifi ed by 
dialysis (≥96%) and characterized by  1 H NMR, UV–vis spec-
troscopy (λ max = 355 nm, ε = 163 300  m −1 cm −1 (FA); 490 nm, 
ε = 121 000  m −1 cm −1 (Dox)), MALDI-TOF spectrometry 
( M r = 40 400 g mol 
−1 ), and other methods as noted above. 
 Values of the valencies of the ligand ( n ) and the caged 
drug ( m ) were determined by Beer–Lambert analysis of 
small 2015, 11, No. 45, 6078–6090
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UV–vis absorption ( A ) at 354 nm (FA) or 490 nm (Dox) 
relative to a standard calibration plot prepared by free FA 
or Dox and by the analysis of NMR peak integration as sum-
marized in Table S1, Supporting Information. The two sets of 
values were consistent with narrow deviations lying within 
±2% of their mean value. 
 2.5.  Light-Controlled Release of Doxorubicin 
 Our earlier studies showed that photochemical cleavage of 
the ortho-nitrobenzyl (ONB; λ max = 340 nm, ε = 2750  m −1 cm −1 ) 
cage occurs rapidly upon exposure to UVA light (365 nm) 
with qunatum effi ciency (Φ) of 0.29. [ 9,34,35 ] We validated the 
light-triggered Dox release from ONB-Dox  3 by monitoring 
its progress with UV–vis spectroscopy and high-performance 
liquid chromatography (HPLC) ( Figure  3 ). Drug release 
was evidenced by changes in the UV–vis spectral traces of 
the light-exposed solutions (0.103 × 10 −3  m in aq methanol) 
compared to unexposed solutions. They showed a gradual 
increase in absorption at 230–280 nm (Figure S8, Supporting 
Information) which is attributable to the cleavage of the 
ONB linker and the formation of nitrosobenzaldehyde as 
suggested previously. [ 9 ] HPLC analysis allowed quantitative 
evaluation of the release kinetics of Dox from  3 . Figure  3 
shows HPLC traces acquired for the photolysed solutions as 
a function of exposure time. Very shortly after irradiation, 
a new peak appeared with a retention time ( t R ) of 7.8 min 
which was identical to that of free Dox. The peak intensity 
increases rapidly as a function of UVA exposure time while 
the peak for ONB-Dox  3 ( t R = 9.8 min) decreases. Area 
under curve (AUC) analysis of the HPLC traces indicated 
that Dox release occurs effi ciently with ≥85% being released 
within 5 min. The rapid decay of ONB-Dox had a fi rst-order 
rate constant of 7.5 × 10 −3 s −1 . 
 An important factor to consider is the attachment site 
of photocaged Dox to the UCN-dendrimer system. Dox-
ONB can either be directly attached to the UCN surface 
or attached through conjugation to the FA-conjugated 
dendrimer. We fi rst investigated whether the kinetics of 
Dox release from ONB-Dox is affected by dendrimer con-
jugation. Light-controlled Dox release from conjugate  8 
small 2015, 11, No. 45, 6078–6090
 Scheme 1.  Synthesis of a) folic acid (FA) derivatized with linker  2 , b) doxorubicin (Dox) caged with an ortho-nitrobenzyl (ONB) group  4 , and c) G5 
dendrimer conjugates  7 and  8 . a) Reagents and conditions : i) PyBOP, HOBt, ( i -Pr) 2 EtN, DMSO, 1.5 h; then 2,2′-(ethylenedioxy)diethylamine (3 mol 
equiv), 18 h; ii) (Boc) 2 O (7 mol equiv), 6 h; iii) CF 3 CO 2 H, CH 2 Cl 2 , 0.5 h; iv) Glutaric anhydride, Et 3 N, MeOH; v) EDC, NHS, 4-dimethylaminopyridine, 
DMF, 12 h; vi)  2 , 7 h; vii)  2 ,  4 , 12 h. Each reaction was performed at room temp.
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G5(FA) 6 (ONB-Dox) 6.9 in water was monitored with UV–vis 
spectrometry and HPLC analysis (Figure  3 ). Changes in the 
UV–vis spectral traces (Figure S8, Supporting Information) 
are evident, showing an increase in absorbance at 280 nm as 
seen with  3 ONB-Dox. Overlaid HPLC traces, each acquired 
after a variable length of UV exposure, showed that the 
broad peaks corresponding to the dendrimer species are 
shifted to faster retention times over the course of UV expo-
sure (Figure  3 d). However, AUC analysis of Dox release was 
not attempted for these HPLC traces since the peak for free 
Dox ( t R = 7.8 min) was entirely buried within the broad den-
drimer peak, and the kinetics of Dox release could not be 
determined for direct comparison with that of free ONB-Dox 
(Figure  3 b). 
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 Figure 3.  a) Light-controlled release of doxorubicin (Dox) from  3 ONB-Dox (top) or  8 G5 dendrimer (bottom) through the cleavage of the ortho-
nitrobenzyl (ONB) cage. b) HPLC traces of  3 (0.103 × 10 −3 M in 10% aq MeOH) after UVA exposure (365 nm), and c) AUC analysis of Dox release (%) 
vs exposure time. d) HPLC and e) GPC traces of  8 (24.8 × 10 −6  M in water) after UVA treatment as a function of exposure time ( t = 0, 10, 30 min). 
inset: %AUC ( t = exposure time) of each peak relative to AUC ( t = 0).
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 We expect that Dox release from conjugate  8 results in 
a change in the distribution of the dendrimer species. We 
examined this by using a novel method based on GPC analysis 
of the photolysed solutions. Elution profi les of the dendrimer 
solution before and after exposure are shown in Figure  3 e. 
The GPC trace for  8 shows a characteristically broad peak 
shape (width at half height =  w h = 7.0 min), which is indica-
tive of a wide dendrimer distribution. This is consistent with 
a prediction by Poissonian simulation [ 36 ] performed for  8 
G5(FA) n (ONB-Dox) m ( n mean = 6;  m mean = 6.9). This Poisson 
analysis suggests that the conjugate solution should consist 
of a large distribution of dendrimer species with variable 
conjugation ratios of the ligand and drug valency ( n = 1–12; 
 m = 2–13; Figure S4, Supporting Information). GPC traces of 
 8 after UV exposure for 10 and 30 min resulted in a signifi -
cant decrease in the  w h to 5.9 min and 5.5 min, respectively. 
This narrower distribution was expected, as the heteroge-
neity would be reduced upon release of the attached Dox 
molecules ( m mean = 6.9 → 0). In addition, the GPC trace after 
30 min exposure shows a similarity in the peak shape and  t R 
when compared to  7 G5(FA) 6 , indicating the effi cient release 
of Dox ( m mean ≈ 0). AUC analysis of the GPC traces (inset, 
Figure  3 e) was performed and the AUC decay as calculated 
as a fi rst-order rate constant (2.8 × 10 −4 s −1 ) occurs at a rate 
≈27-fold lower than free ONB-Dox by HPLC. 
 These results demonstrate that UV light serves as an 
effective trigger for the active control of Dox release from the 
ONB photocaged form. Interestingly, Dox release occurred 
faster from ONB-Dox  3 than from the FAR-targeted den-
drimer  8 carrying the photocaged Dox. These observed dif-
ferences have not been reported in literature and may be 
due to the presence of FA coattached to the dendrimer. The 
pteridine chromophore in FA has signifi cant UV absorptivity 
(λ max = 354 nm; ε = 62 800  m −1 cm −1 ) which can effectively 
compete with the ONB linker for light absorption. Thus, 
this release study suggests that attachment of ONB-Dox 
to the UCN is more preferable than to the FA-conjugated 
dendrimer. 
 2.6.  Binding Avidity of G5(FA) Conjugates 
 In our UCN-based core/shell nanostructure, the outer shell 
layer is comprised of the FA-conjugated dendrimer module 
which confers FAR-targeting properties to the nanostructure. 
We determined the multivalent binding avidity ( K D ) of FA-
conjugated dendrimers  7 , and  8 to the receptor on the surface 
using SPR spectroscopy. SPR is highly suited for studying 
multivalent receptor-ligand interactions that occur on the cell 
surface. [ 18c ,  37 ] 
 Folate binding protein (FBP) was immobilized on the 
sensor chip surface as a model receptor for FAR overex-
pressed on a tumor cell. [ 18c ,  19c ,  25 ] The FBP model surface 
was prepared following a standard EDC/NHS-based amide 
coupling method [ 18c ] at a protein density of 13.1 ng mm −2 
(response unit (RU) = 13090; Figure S6, Supporting Infor-
mation). This FBP density is equivalent to a number den-
sity of ≈2.6 × 10 11 FBP molecules per mm 2 , comparable to 
the density of FAR overexpressed in several malignant 
cell lines including ovarian and endometrial cancers [ 38 ] 
(≈10 10 –10 11 receptor molecules per mm 2 ). [ 18c ] The affi nity of 
the immobilized FBP to FA was determined by acquiring 
dose-dependent sensorgrams (Figure S7a, Supporting Infor-
mation). Each of the sensorgrams was fi t according to a global 
curve fi tting analysis based on a Langmuir model (1:1 binding 
mode) to determine the two rate constants:  k a (association) 
and  k d (dissociation). 
[ 39 ] Using these two kinetic parameters, 
we calculated an equilibrium dissociation constant  K D 
(=  k d k a ) of 5.9 × 10 
−6  m ( Table  1 ), comparable to those 
reported in the literature ( K D = 2–5 × 10 
−6  m ). [ 18c ] 
 SPR experiments performed with  7 G5(FA) 6 showed 
dose-dependent adsorption of the dendrimer to the FBP 
surface (Figure S7b, Supporting Information). Adsorption 
was detectable at ≤0.16 × 10 −6  m , a concentration at which no 
binding is detectable by free FA, indicating tighter binding 
of the dendrimer conjugate than free FA alone. Further-
more, this conjugate dissociates much more slowly than FA. 
Such markedly slow desorption is consistent with earlier 
studies that show slow dissociation kinetics of other multiva-
lent G5(FA) n and G5(MTX) n ( n ≥ 3; MTX = methotrexate) 
conjugates. [ 18c ,  24c ] Global fi tting analysis gave a  k d value cor-
responding to a ≈10-fold slower rate of desorption by  7 than 
FA (Table  1 ). This slow dissociation is a kinetic feature that 
contributes to the high avidity binding commonly associated 
with multivalent systems. [ 17b ,  17c ] From this SPR analysis, the 
 K D value for  7 was determined as 5.9 × 10 
−9  m , refl ecting high 
binding avidity with a multivalent enhancement factor of 167 
(valency corrected). 
 Finally, the SPR experiments were performed with  8 
G5(FA) 6 (ONB-Dox) 6.9 , which is identical to  7 G5(FA) 6 in its 
FA valency but in addition carries an ONB-Dox payload. This 
conjugate showed faster apparent dissociation than  7 . Its mean 
fractional desorption (= (RU desorption /RU adsorption ) × 100%; 
see Figure S7, Supporting Information) calculated at the end 
of the dissociation phase ( t = 600 s; 88 ± 2%) was larger than 
that of  7 G5(FA) 6 ( t = 600 s; ≈37 ± 12%; Figure S7, Supporting 
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 Table 1.  Kinetic parameters and equilibrium dissociation constants of FA,  7 G5(FA) 6 and  8 G5(FA) 6 (ONB-Dox) 6.9 to a CM5 sensor chip immobilized 
with folate binding protein (FBP). 
Dendrimer  k a 
a) [ M −1 s −1 ]  k d 
a) [s −1 ]  K D 
b) [ M ] β c) 
FA 1.5 × 10 3 9.0 (±2.9) × 10 –3 5.9 × 10 –6 1.0
 7 G5(FA) 6 1.5 × 10 
5 8.5 (±5.3) × 10 –4 5.9 × 10 –9 1,000 (167 d) )
 8 G5(FA) 6 (ONB-Dox) 6.9 1.7 × 10 
5 2.8 (±0.36) × 10 –3 1.7 × 10 –8 347 (58 d) )
 a) Mean value (±SD) from serially diluted concentrations ( n ≥ 4);  b) K D =  k d / k a ;  c) Multivalent enhancement factor =  K D (FA)/ K D (dendrimer);  d) Valency corrected = multivalent enhancement factor/6 
(= FA valency). 
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Information). Such greater desorption of  8 
is largely explained by its ≈3-fold higher  k d 
value which leads to lower avidity with a 
 K D value of 1.7 × 10 
−8  m . We believe this 
reduction in avidity is caused primarily by 
an unfavorable steric effect [ 19b ,  40 ] in which 
the extended dendritic branches with 
the ONB-Dox might interfere with the 
optimal multivalent association between 
the multiple FA ligands and the receptors 
on the surface. 
 In summary, this SPR binding study 
demonstrated high avidity binding by 
FA-conjugated dendrimers to FBP recep-
tors on the cell surface. However it was 
also evident that the copresence of a drug 
payload carried by the ligand-conjugated 
dendrimer compromises the targeting 
capability of the dendrimer carrier. These 
SPR results along with the slower rate 
of drug release observed for the dual-
functional module as described above led 
us to rationally identify a better design 
approach for the UCN core/shell, in which 
the two separate modules,  7 G5(FA) 6 and 
ONB-Dox are directly attached to the 
UCN core independently. 
 2.7.  Covalent Integration of UCNs with 
G5(FA) and ONB-Dox 
 Dendrimer conjugation to the UCN was 
performed by amide coupling between a 
carboxylic acid residue in  7 G5(FA) 6 and 
an amine residue present in (NH 2 )SiO 2 -
coated UCN x (type  x = 1, 2). It is illustrated by an EDC-
based covalent attachment of  7 to UCN 1 in the synthesis 
of  9 UCN 1 @(G5FA) ( Scheme  2 a). This dendrimer-coated 
UCN was further modifi ed for imaging purposes by conjuga-
tion with a sulfo-Cy5 to yield  10 UCN 1 @(Cy5)(G5FA). We 
attached the Cy5 dye (λ ex = 600 nm, λ em = 667 nm) to the 
nanostructure as a secondary probe for vis imaging in addi-
tion to the primary NIR imaging properties of the UCN core 
in order to measure cellular uptake. The UV–vis spectra of 
these UCN suspensions show an increase in the absorption 
range (≈240–400 nm) which is attributable to FA absorption 
(Scheme  2 c). In addition, the presence of the sulfo-Cy5 label 
on  10 is clearly indicated by the characteristic fl uorescence 
emission spectrum (λ ex = 600 nm, λ em = 667 nm; inset). 
 Coattachment of  7 G5(FA) 6 and  4 ONB-Dox to UCN 
was performed by a slightly modifi ed method because of the 
need for a surface modifi cation that allows crosslinking with 
amine-containing  4 (Scheme  2 b). Thus, (NH 2 )SiO 2 -coated 
UCN was treated with epibromohydrin which converts some 
of its surface amine residues to amine-reactive epoxide resi-
dues. This modifi ed UCN reacted with  4 ONB-Dox, affording 
drug-crosslinked  11 and  12 UCN@(ONB-Dox). UV–vis spec-
trometry was used to determine the fraction of ONB-Dox 
attached to the UCN by analysis of the ONB-Dox solution 
(λ max = 495 nm) before and after the conjugation reaction. 
The fi ndings suggested that the weight fraction of ONB-Dox 
to UCN (w/w) was approximately 3.5% ( 11 ) and 6.5% ( 12 ) 
(the Supporting Information). In the next step,  7 G5(FA) 6 was 
attached by EDC-based amide coupling to  11 or  12 UCN x @
(ONB-Dox), which resulted in  13 and  14 UCN x @(ONB-Dox)
(G5FA) ( x = 1, 2), respectively (TEM images of  13 and  14 
provided in Figure S5, Supporting Information). The effi -
ciency of this dendrimer conjugation was estimated by UV–
vis analysis, indicating that ≈9% of the dendrimer added in 
large excess in the reaction was covalently attached. UV–vis 
spectra overlaid in Scheme  2 d show corresponding changes 
in the absorption λ max values and intensities indicative of sur-
face modifi cation of UCN with ONB-Dox (λ max = 498 nm) 
and G5(FA) 6 (λ max = 200–220 nm). 
 2.8.  Confocal Imaging Study of UCN@(G5FA) in KB Cells 
In Vitro 
 To examine the cellular binding and uptake of the UCN 
nanostructures, we treated FAR-overexpressing (+) KB 
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 Scheme 2.  Synthesis of various UCN-based core/shell nanostructures, each conjugated with 
G5(FA) 6 , Cy5 dye and/or ONB-Dox. 
a) a)  10 UCN1@(Cy5)(G5FA); b)  13 ,  14 UCN x @(ONB-Dox)
(G5FA) ( x = 1, 2); c,d) UV–vis absorption spectra b),c) and fl uorescence emission spectrum d) 
(c; inset) of selected nanostructures.  a) Reagents and conditions: i)  7 G5(FA) 6 , EDC, NHS, DMF, 
rt, 13 h; ii) Sulfo-Cy5 NHS ester, DMSO, rt; iii) epibromohydrin, MeOH, rt; then  4 ONB-Dox, 
rt to 45 °C.  b) [ 9 or  10 ] = 1 mg mL −1 water, [ 7 ] = 62.5 µg mL −1 water;  c) [ 12 or  14 ] = 1 mg mL −1 
MeOH;  d) [ 10 ] = 0.25 mg mL −1 MeOH; λ ex = 600 nm, λ em = 667 nm.
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tumor cells with increasing concentrations (50–500 µg mL −1 ) 
of  9 UCN 1 @(G5FA) or  10 UCN 1 @(Cy5)(G5FA) for 2 h, 
and imaged the cells with confocal microscopy using two 
detection modes: (i) Cy5 mode (λ ex = 640 nm; λ ex = 670 nm) 
and (ii) UCN 1 NIR mode (λ ex = 980 nm; λ ex = 550, 650 nm). 
As shown in  Figure  4 , confocal images of the cells with  10 
clearly indicated dose-dependent binding and uptake by 
KB cells (Figure  4 a–c). No signal was detected through this 
Cy5 channel in cells treated with  9 , an identical nanoparticle 
without the Cy5 attachment, confi rming that the fl uorescence 
signal is from the Cy5 (Figure  4 d). 
 We then imaged the treated cells in NIR mode with exci-
tation at 980 nm and detection at 550 or 650 nm (Figure  4 ). 
The localization of FAR-targeted UCNs on the cell surface 
as well as intracellularly was observed under both the NIR 
and Cy5 imaging modes in cells treated with  10 (200 or 
500 µg mL −1 ). Merged images showed colocalization of the 
NIR and Cy5 signals, demonstrating the ability to image 
UCNs with either mode of detection (Figure  4 e,f). Further-
more, UCN  9 could be detected under the NIR mode despite 
the absence of the Cy5 label (Figure  4 g,h). Thus, visible 
light-emitting UCN 1 serves as an effective platform for label 
free cellular imaging with NIR excitation. 
 2.9.  Flow Cytometric Analysis of UCN@(G5FA) Binding 
and Uptake in KB Cells In Vitro 
 Cellular association of  10 UCN 1 @(Cy5)(G5FA) was further 
investigated by fl ow cytometry. Two cell lines which are dis-
tinct in their FAR density were used to determine the speci-
fi city of UCN in FAR targeting: FAR(+) KB cells and FAR(−) 
B16-F10 cells (a mouse melanoma cell line). Cells were incu-
bated with variable concentrations of  10 (0–50 µg mL −1 ) for 
1 h in FA-free media at 37 °C and analyzed. Histograms and 
fl uorescence intensities (FL3 for Cy5) of gated live cells are 
shown in  Figure  5 . The fraction of KB cells with bound  10 
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 Figure 4.  Cellular binding and uptake of  9 UCN 1 @(G5FA) and  10 
UCN 1 @(Cy5)(G5FA) in FAR(+) KB cells imaged by confocal microscopy. 
a–d) Images of KB cells treated with  10 or  9 taken in Cy5 mode (λ ex = 
640 nm; λ em = 670 nm). e–h) Images of KB cells treated with  10 or  9 
taken in both NIR mode for imaging the UCN core (λ ex = 980 nm; λ em = 
550 nm, 650 nm) and Cy5 mode. DAPI (blue: nuclei); UCN core (red), 
Cy5 (green).
 Figure 5.  a,b) Flow cytometric analysis of binding and uptake of 
 10 UCN 1 @(Cy5)(G5FA) by FAR(+) KB cells and FAR(−) B16 F10 cells. 
c) Fraction of cells with bound or internalized UCN, determined by the 
percentage of cells with Cy5 fl uorescence (FL3) greater than that of cells 
alone (gate M1). Each data point represents a mean value of duplicate 
measurements (±SD).
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increased in a dose-dependent manner. In contrast, FAR(−) 
B16 cells showed only a small fraction of cells with bound 
UCN under the same conditions (Figure  5 b). The frac-
tion of bound cells determined at the highest concentration 
(50 µg mL −1 ) was 44 ± 19% for FAR(+) KB cells compared to 
only 11 ± 3% for FAR(−) B16 cells. These results support the 
specifi c binding and uptake of  10 UCN 1 @(Cy5)(G5FA) by a 
FAR-dependent mechanism. As evidence further supporting 
FAR specifi city, cells were incubated with  10 (10 µg mL −1 
UCN equivalent to ≈0.02 × 10 −6  m FA) in the presence of 
free FA (50 × 10 −6 m ) to verify whether FA could competi-
tively inhibit nanoparticle adsorption to KB cells. Addition of 
50 × 10 −6 m FA led to a decrease in the fraction of cells with 
bound UCN from 44% to 31%. This competitive inhibition is 
supportive of FAR-specifi c cell binding, though such a small 
effect is perhaps due to the weaker µM affi nity of FA relative 
to the higher affi nity of the multivalent dendrimer attached 
to the UCN. 
 FAR-specifi c cell binding by  10 is consistent with ear-
lier results observed with FAR-targeted dendrimers such 
as G5(FA) 6.4 (ONB-Dox) 5.9 and G5(MTX) 10 . 
[ 9 ,  18c ,  24c ] The 
binding avidity of  10 to a FAR model surface was not meas-
urable by SPR because of its suspension-like nature (due to 
low solubility in water), however we believe that such cell 
specifi city is primarily attributable to the tight multivalent 
interactions between multiple G5(FA) 6 dendrimers in the 
shell layer and the cell surface receptors as suggested by the 
SPR study above ( K D = 5.9 × 10 
−9  m ; Table  1 ). 
 2.10.  Light-Controlled Cytotoxicity of UCNs Conjugated 
with ONB-Dox 
 Lastly, we evaluated the effi cacy of two different types of 
light excitation for the controlled induction of cytotoxicity 
by  13 UCN 1 @(ONB-Dox)(G5FA) or  14 UCN 2 @(ONB-Dox)
(G5FA) in FAR(+) KB cancer cells ( Figure  6 ).  13 consists of 
3.5% (w/w)  4 ONB-Dox: UCN conjugate and  14 consists of 
6.5% (w/w)  4 ONB-Dox: UCN conjugate. We employed this 
cell-based assay primarily to compare the overall cytotoxicity 
of each UCN conjugate triggered by UV and NIR irradia-
tion. This assay allows direct determination of the functional 
activity of decaged (activated) drug molecules by addressing 
both the release effi ciency and penetration capability of 
each light source through cellular membranes. UV light was 
fi rst validated as a reference light source for Dox release. 
KB cells were treated with  13 or  14 and the cell viability 
was determined under two different exposure conditions 
(Figure S9, Supporting Information): “pre-exposed 0.5 h” and 
“1 h exposure on cells.” In the fi rst condition (“pre-exposed 
0.5 h”), the test solution alone in PBS/1% BSA (PBSB) was 
exposed to UV light (365 nm) for 0.5 h prior to its addition 
to and incubation with the cells for 1.5 hat 37 °C. In the other 
condition (“1 h exposure on cells”), the cells were incubated 
with each test solution in PBSB and the entire mixture of 
cells with UCN was exposed to UV light for 1 h followed by 
incubation at 37 °C for an additional 0.5 h. Fresh media was 
added to all of the treated cells to dilute the conjugate by a 
factor of four, and the cells were incubated for 24 h prior to 
replacing the conjugate containing media with fresh media. 
Viability was measured after 4 d of incubation at 37 °C in 
this fresh media. 
 As shown in Figure  6 a,b, The KB cells were treated with 
 13 or  14 suspended at two concentrations: 500 µg mL −1 : 
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 Figure 6.  Light-controlled cytotoxicity of  13 UCN 1 @(ONB-Dox)(G5FA) 
and  14 UCN 2 @(ONB-Dox)(G5FA) in FAR(+) KB cancer cells. (a, b) Viability 
(%) of cells treated with  13 or  14 and exposed to a UV lamp (365 nm; 
15 W; output = ≈3 × 10 19 photons s −1 ) under two different conditions 
as defi ned in the text. Each data point refers to a mean value (±SD; 
 n ≥ 3). c) Viability (%) of cells treated with  14 ([UCN] = 750 µg mL −1 ), 
each with or without exposure to a continuous wave NIR laser (980 nm; 
1 W; output = ∼5 × 10 18 photons s −1 ) or a UV lamp for 1 h exposure on 
cells. Each bar represents a mean value (±SD;  n ≥ 5).
full papers
www.MaterialsViews.com
6088 www.small-journal.com © 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim small 2015, 11, No. 45, 6078–6090
equivalent [ONB-Dox] = 20 × 10 −6  m ( 13 ), 30 × 10 −6  m ( 14 ); 
750 µg mL −1 : [Dox-ONB] = 37 × 10 −6  m ( 13 ), 56 × 10 −6  m ( 14 ). 
Treatment at the lower concentration was ineffective regard-
less of light exposure. In contrast, treatment at the higher 
concentration led to a marked decrease in viability and was 
highly dependent on the conditions of the light exposure. 
In particular, the “exposure on cells” condition in which the 
cells were incubated with the UCN prior to being exposed 
to UV light was the most effective in killing the cells. Simi-
larly, the KB cells were treated with  4 ONB-Dox and  8 
G5(FA) 6 (Dox) 6.9 as positive controls under various condi-
tions of light exposure, as summarized in Figure S10, Sup-
porting Information. This study validated the light control of 
Dox release from the UCN conjugates, and also allowed us to 
identify a threshold nanoparticle dose for inducing cytotox-
icity in KB cells in a light dependent manner. 
 In contrast to conjugate  13 which contains a UCN 1 core 
that only emits in the visible range, conjugate  14 consists of 
a UCN 2 core that emits UV light (λ em = 345, 362 nm) upon 
excitation with NIR (980 nm) (Figure  2 ). We thus investi-
gated whether excitation of  14 UCN 2 @(ONB-Dox)(G5FA) 
with NIR could trigger drug release and subsequently 
result in cytotoxicity. FAR(+) KB cells were treated with 
750 µg mL −1 the UCN conjugate and the cells were exposed 
to NIR radiation (980 nm; power output = 1 W) for 1 h (“1 h 
exposure on cells”). Figure  6 c compares the effect of expo-
sure to NIR and UV light to dark controls. Cells showed no 
signifi cant decrease in viability in the presence or absence 
of  14 without any exposure to light excitation. Exposure to 
UV or NIR light for the treatment period also did not have 
any signifi cant impact on cell viability. However, exposure of 
cells treated with  14 to NIR light led to a signifi cant decrease 
in cell viability comparable to that induced by the direct 
cleavage of the photocaged Dox by UV triggered release. 
 Cytotoxicity as triggered by NIR, however, showed a 
wider variation (±SD) in activity. We believe this experi-
mental error is attributable to a number of technical chal-
lenges facing the NIR exposure. First, unlike the UV release 
which was performed under a UV lamp, NIR release was 
performed by irradiation with a continuous wave (CW) NIR 
laser. Thus the wide variation between replicates could have 
been due to the lack of homogeneous excitation across each 
sample well due to the relatively small size of the laser beam. 
Second, NIR release requires an extended period of irradi-
ation (1 h) primarily due to the low quantum yield of UV 
emission from UCN 2 as illustrated by the low intensity of its 
UV emission peaks relative to the intensity of UCN 1 visible 
emission (Figure  2 ). Despite such technical challenges that 
need to be addressed, we believe that this NIR release study 
supports the use of the UCN core as an effective way to con-
trol drug release by NIR radiation. 
 3.  Conclusion 
 In summary, in this study, we employed a bottom-up approach 
toward the modular integration of UCN with a FAR-targeted 
multivalent dendrimer G5(FA) 6 and photocaged doxorubicin 
ONB-Dox. Integration of these three individually functional 
components into a single nanostructure could be achieved 
through a variety of conceivable combinations. Many design 
aspects fundamental to this type of UCN integration (ex. 
drug or targeting ligand attachment sites) have not been sys-
tematically evaluated in previous studies. [ 2 ,  5b ,  6a–e ] 
 The rationale for designing such composite UCN nano-
structures lies in the unique optical properties conferred by 
the UCN cores, in which the UCN core selectively absorbs 
focused NIR (980 nm) light and emits UV–vis light, [ 5g ,  6a,b,d ] 
thus serving as a light emitting nanodevice. Two UCN types 
were designed: UCN 1 (λ em = 542, 651 nm) suitable for vis 
imaging and UCN 2 (λ em = 340–360, 450–475 nm) suitable 
for light-controlled drug release. UCN 1 @(G5FA) enabled 
the use of NIR imaging for sensitive, label-free detection of 
FAR(+) carcinoma cells. Furthermore, UCN 2 integration into 
the UCN 2 @(ONB-Dox)(G5FA) nanocomposite allowed for 
effective targeted drug delivery triggered by either UV or 
NIR irradiation. Our approach for the controlled release of 
Dox is based on its temporary inactivation with a UV light-
cleavable cage, an  ortho -nitrobenzyl (ONB) group. UVA 
light penetrates through the skin, reaching cells in the layers 
of the epidermis and dermis (depth ≤0.15 mm), [ 41 ] providing 
a potentially spatial mechanism of drug release to tumor cells 
localized to the skin and vascular endothelial cells. However, 
the use of UV-triggered photorelease for targeting more 
interiorly located tumors is limited by the penetration depth 
of UV excitation. Integration of the photocaged drug with 
UCNs, however, allows for the use of a NIR excitation light 
source in place of UV to trigger drug release using the same 
UV-cleavable photocage due to the UV emission of the UCN 
core upon excitation with NIR. This ability to trigger drug 
delivery with NIR enables the use of photocontrolled drug 
delivery to target more interiorly localized cells, as NIR light 
penetrates deep into tissues (depth ≥2–3 mm) without a sig-
nifi cant loss of transmission from absorption by water. [ 41 ] We 
believe that these novel NIR-excited UCN nanocomposite 
structures have great potential for extending the scope of 
imaging and drug release from UV-accessible skin cells to 
other tissues and inner organs of interest. Furthermore, the 
lower energy of NIR makes it more desirable as a treatment 
light source relative to UVA, which while less damaging than 
UVB, still has the potential to damage bystander cells upon 
prolonged exposure. 
 Two modes for structural integration of photocaged doxo-
rubicin ONB-Dox were examined: conjugation to G5(FA) 6 
or direct conjugation to the UCN. Our fi ndings suggested 
potentially greater benefi ts through the direct attachment of 
photocaged drug to the UCN surface. Coconjugation of ONB-
Dox and FA to the PAMAM dendrimer G5(FA) 6 (ONB-Dox) 
resulted in lower binding avidity to the model surface for a 
FAR(+) cell compared to G5(FA) 6 perhaps due to steric inter-
ference from the bulky Dox molecule blocking FAR access 
to the FA ligand molecule. In the UV-mediated drug release 
study, Dox release occurred faster from ONB-Dox than from 
the dendrimer conjugated form G5(FA) 6 (ONB-Dox). Thus, 
cell receptor targeting avidity and specifi city as well as drug 
release kinetics from UCN nanocomposites appear to be 
highly dependent on the site of conjugation of the targeting 
ligand and photocaged drug payload. Considering all of these 
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data together, this study provides implications of signifi cant 
importance to the design and screening of multifunctional 
UCN nanostructures for surface receptor-targeted imaging 
and treatment of tumor cells. 
 4.  Experimental Section 
 Methods for the synthesis of UCNs, G5 PAMAM dendrimer and 
photocaged Dox, and analytical methods (TEM, HPLC, GPC,  1 H 
NMR, UV–vis spectrometry, MALDI-TOF mass spectrometry) are 
described in detail in the Supporting Information and references 
cited therein. Full details for other materials and methods (drug 
release kinetics, SPR spectroscopy, cell culture, fl ow cytom-
etry, confocal microscopy) are also provided in the Supporting 
Information. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library 
or from the author. 
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